ABOS - Acumen Pharmaceuticals

-

$undefined

N/A

(N/A)

Acumen Pharmaceuticals NasdaqGS:ABOS Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Location: 1210-1220 Washington St., Newton, MA, 02465, United States | Website: https://acumenpharm.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-57.58M

Cash

149.1M

Avg Qtr Burn

-25.62M

Short % of Float

5.70%

Insider Ownership

11.41%

Institutional Own.

72.20%

Qtr Updated

03/31/25